Remdesivir, A Potential Drug for COVID-19 Treatment: A New Hope

(E-pub Ahead of Print)

Author(s): Kuldeep Singh, Dilpreet Singh*, Karan Razdan

Journal Name: Coronaviruses
The World's First International Journal Dedicated to Coronaviruses

Become EABM
Become Reviewer
Call for Editor


Objective: Coronavirus Diease-2019 (COVID-19) is a pandemic outbreak in the world and is the leading cause of Severe Acute Respiratory Syndrome (SARS).

Methods: Currently, many drugs/therapies have been tested for COVID-19 which responded sub optimally to the patients. Remdesivir is a RNA polymerase inhibitor found promising results in ongoing clinical trials and shows faster recovery rate in COVID-19 patients. Currently, USFDA approves for emergent use of this drug in severe COVID-19 patients.

Results: In this review, we discussed brief overview of biopharmaceutical and pharmacological aspects of Remdesivir. Moreover, ongoing regulatory status of Remdesivir by official bodies has also been described.

Keywords: Remdesivir, COVID-19, USFDA, SARS, WHO, RNA polymerase inhibitor

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/2666796701999201218141652